Immune System Diseases

926 trials 377 recruiting

Filter these 926 trials by phase, country and sponsor.

Open in Search →

A study to investigate the effects of multiple doses of obefazimod on a combined oral contraceptive (ethinyl estradiol/drospirenone) in hea… Ended

2023-505297-15-00 Healthy female participants of childbearing potential. 3 2023-10-10
A multicenter, single arm, open-label trial to evaluate efficacy and safety of oral, twice daily iptacopan in adult PNH patients who have Hb… Ended

2022-502148-10-00 Paroxysmal Nocturnal Hemoglobinuria (PNH) 5 2023-10-10
A Study to Evaluate the Safety and Tolerability of JNJ-77730614 When Given as Single and Multiple Doses to Healthy Participants to Assess Ho… Ended

2023-505684-36-00 Healthy Volunteers 1 2023-10-09
A Phase I study to evaluate the pharmacokinetics, safety, and tolerability of multiple oral doses of obefazimod in patients with mild and mo… Ended

2023-505299-31-00 Ulcerative colitis and rheumatoid a1thritis 3 2023-10-09
Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency as Open Label Extension Ended

2023-504534-21-00 18 driven monogenic autoinflammatory conditions: NLRC4 5 2023-10-09
A Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis Ended

2022-501621-20-00 Prurigo Nodularis 5 2023-10-02
Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma (ALPHA2) Ended

2022-501927-25-00 Large B-Cell Lymphoma (LBCL) 4 2023-09-29
A Phase 3 Study of Obexelimab in Patients with Warm Autoimmune Hemolytic Anemia Ended

2022-501005-12-00 WARM AUTOIMMUNE HEMOLYTIC ANEMIA 5 2023-09-22
A Multi-national Phase IIIb Trial to Determine the Safety and Efficacy of STALORAL® Birch 300 IR in Children and Adolescents 5 to 17 Years o… Ended

2023-509833-38-00 Birch Pollen-induced Allergic Rhinoconjunctivitis 5 2023-09-20
A Phase 2 proof of concept study to evaluate the efficacy and safety of daxdilimab in participants with dermatomyositis or anti-synthetase i… Ended

2022-502810-10-00 Dermatomyositis (DM) or anti-synthetase inflammatory my 4 2023-09-12
Long-term extension study of ligelizumab in food allergy Ended

2022-502366-25-00 Food allergy 5 2023-09-11
Study of Leniolisib in Pediatric Patients (Aged 4 to 11 Years) with APDS (Activated Phosphoinositide 3-Kinase Delta Syndrome) Ended

2024-515489-15-00 Activated Phosphoinositide 3-Kinase Delta Syndrome 5 2023-09-06
A Study to Evaluate the Efficacy and Safety of Vixarelimab Compared with Placebo in Patients with Idiopathic Pulmonary Fibrosis and in Patie… Ended

2022-502828-42-00 Idiopathic Pulmonary Fibrosis 4 2023-09-01
A Study to Learn About the Study Medication Called Etrasimod Mini Tablets, Including Its Taste, When Mixed With Applesauce, Chocolate Puddin… Ended

2023-504411-32-00 immune-mediated inflammatory disorders, including ulcer 3 2023-08-23
PREPARE-iVAC Ended

2023-503894-39-00 kidney transplantation 11 2023-08-22
Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from birch pollen allergy Ended

2023-505567-37-00 Moderate-to-severe allergic rhinitis / rhinoconjunctivi 10 2023-08-22
A Phase I (First-in-Human) Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and… Ended

2023-504450-35-00 Plaque psoriasis 1 2023-08-21
A multicentre, randomised, double-blind, placebo-controlled, 12-week parallel-group trial to evaluate the efficacy and safety of oral BP1.78… Ended

2022-502045-10-00 Atopic dermatitis 4 2023-08-11
The Italian Cohort (ITACO) and the Analytical Antiretroviral Treatment Interruption Italian Cohort (ITACO-ATI) study guided by molecular HIV… Ended

2024-518694-33-00 perinatally HIV infection 5 2023-08-08
A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) The… Ended

2024-513329-22-00 Lupus Nephritis 7 2023-07-20
A study investigating the absorption and food effect of different tablet formulations of JNJ-77242113, a new compound in the treatment of in… Ended

2023-504720-26-00 Inflammatory Conditions 3 2023-07-19
TRIAL EVALUATING EFFICACY AND SAFETY OF HYDROXYCHLOROQUINE VERSUS PLACEBO IN EARLY SYSTEMIC SCLEROSIS (SSc) Ended

2024-516050-22-00 Systemic Sclerosis (SSc) is a rare and orphan disease ( 5 2023-07-13
A Phase 3 Study Investigating the Efficacy, Safety, and Tolerability of Ritlecitinib in Participants with Nonsegmental Vitiligo Ended

2022-501668-16-00 NON SEGMENTAL VITILIGO 5 2023-06-26
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (S… Ended

2022-501752-29-00 Hidradenitis Suppurativa 5 2023-06-15